
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9223777/publications.pdf Version: 2024-02-01



ΗΛΙ-CHUN ΥΛΝΟ

#	Article	IF	CITATIONS
1	Kidney Injury Causes Accumulation of Renal Sodium That Modulates Renal Lymphatic Dynamics. International Journal of Molecular Sciences, 2022, 23, 1428.	4.1	7
2	Lipopolysaccharide Pretreatment Prevents Medullary Vascular Congestion following Renal Ischemia by Limiting Early Reperfusion of the Medullary Circulation. Journal of the American Society of Nephrology: JASN, 2022, 33, 769-785.	6.1	10
3	DDR1 contributes to kidney inflammation and fibrosis by promoting the phosphorylation of BCR and STAT3. JCI Insight, 2022, 7, .	5.0	24
4	Holistic fine-grained global glomerulosclerosis characterization: from detection to unbalanced classification. Journal of Medical Imaging, 2022, 9, 014005.	1.5	2
5	Podocyte-Related Mechanisms Underlying Survival Benefit of Long-Term Angiotensin Receptor Blocker. International Journal of Molecular Sciences, 2022, 23, 6018.	4.1	Ο
6	Blocking cell cycle progression through CDK4/6 protects against chronic kidney disease. JCI Insight, 2022, 7, .	5.0	9
7	Glo-In-One: holistic glomerular detection, segmentation, and lesion characterization with large-scale web image mining. Journal of Medical Imaging, 2022, 9, .	1.5	4
8	Stabilization of hypoxia-inducible factor ameliorates glomerular injury sensitization after tubulointerstitial injury. Kidney International, 2021, 99, 620-631.	5.2	13
9	Adapting decarbonylation chemistry for the development of prodrugs capable of <i>in vivo</i> delivery of carbon monoxide utilizing sweeteners as carrier molecules. Chemical Science, 2021, 12, 10649-10654.	7.4	23
10	Increased dishevelled associated activator of morphogenesis 2, a new podocyte-associated protein, in diabetic nephropathy. Nephrology Dialysis Transplantation, 2021, 36, 1006-1016.	0.7	4
11	Al applications in renal pathology. Kidney International, 2021, 99, 1309-1320.	5.2	42
12	High-Density Lipoproteins in Kidney Disease. International Journal of Molecular Sciences, 2021, 22, 8201.	4.1	9
13	Kidney injury-mediated disruption of intestinal lymphatics involves dicarbonyl-modified lipoproteins. Kidney International, 2021, 100, 585-596.	5.2	11
14	Protocol for multimodal analysis of human kidney tissue by imaging mass spectrometry and CODEX multiplexed immunofluorescence. STAR Protocols, 2021, 2, 100747.	1.2	14
15	Map3D: Registration-Based Multi-Object Tracking on 3D Serial Whole Slide Images. IEEE Transactions on Medical Imaging, 2021, 40, 1924-1933.	8.9	10
16	Instance segmentation for whole slide imaging: end-to-end or detect-then-segment. Journal of Medical Imaging, 2021, 8, 014001.	1.5	10
17	Quantitative Super-Resolution Microscopy Reveals Promoting Mitochondrial Interconnectivity Protects against AKI. Kidney360, 2021, 2, 1892-1907.	2.1	6
18	Biotic Supplements in Patients With Chronic Kidney Disease: Meta-Analysis of Randomized Controlled Trials. , 2021, , .		13

#	Article	IF	CITATIONS
19	Cell-Mediated Glomerulonephritis Without Immune Complexes in Native Kidney Biopsies: A Report of 7 Cases. American Journal of Kidney Diseases, 2021, , .	1.9	0
20	IL-6-mediated hepatocyte production is the primary source of plasma and urine neutrophil gelatinase–associated lipocalin during acute kidney injury. Kidney International, 2020, 97, 966-979.	5.2	40
21	Renal lymphatic vessel dynamics. American Journal of Physiology - Renal Physiology, 2020, 319, F1027-F1036.	2.7	13
22	The authors reply. Kidney International, 2020, 98, 232-233.	5.2	8
23	AKI and Collapsing Glomerulopathy Associated with COVID-19 and APOL 1 High-Risk Genotype. Journal of the American Society of Nephrology: JASN, 2020, 31, 1688-1695.	6.1	204
24	Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney International, 2020, 98, 219-227.	5.2	1,388
25	CircleNet: Anchor-Free Glomerulus Detection with Circle Representation. Lecture Notes in Computer Science, 2020, 2020, 35-44.	1.3	23
26	Tubular \hat{I}^2 -catenin and FoxO3 interactions protect in chronic kidney disease. JCI Insight, 2020, 5, .	5.0	19
27	Urinary apoAl: novel marker of renal disease?. Pediatric Nephrology, 2019, 34, 2425-2426.	1.7	2
28	Cell-free hemoglobin augments acute kidney injury during experimental sepsis. American Journal of Physiology - Renal Physiology, 2019, 317, F922-F929.	2.7	26
29	Capillary rarefaction is more closely associated with CKD progression after cisplatin, rhabdomyolysis, and ischemia-reperfusion-induced AKI than renal fibrosis. American Journal of Physiology - Renal Physiology, 2019, 317, F1383-F1397.	2.7	38
30	Mechanisms of Scarring in Focal Segmental Glomerulosclerosis. Journal of Histochemistry and Cytochemistry, 2019, 67, 623-632.	2.5	9
31	Matching Human Unilateral AKI, a Reverse Translational Approach to Investigate Kidney Recovery after Ischemia. Journal of the American Society of Nephrology: JASN, 2019, 30, 990-1005.	6.1	30
32	Fibroblast-specific plasminogen activator inhibitor-1 depletion ameliorates renal interstitial fibrosis after unilateral ureteral obstruction. Nephrology Dialysis Transplantation, 2019, 34, 2042-2050.	0.7	20
33	Lipoprotein modulation of proteinuric renal injury. Laboratory Investigation, 2019, 99, 1107-1116.	3.7	9
34	Low-grade albuminuria in pulmonary arterial hypertension. Pulmonary Circulation, 2019, 9, 204589401882456.	1.7	11
35	Kidney as modulator and target of "good/bad―HDL. Pediatric Nephrology, 2019, 34, 1683-1695.	1.7	14
36	Angiotensin receptor blocker vs ACE inhibitor effects on HDL functionality in patients on maintenance hemodialysis. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 582-591.	2.6	5

#	Article	IF	CITATIONS
37	ASK1 contributes to fibrosis and dysfunction in models of kidney disease. Journal of Clinical Investigation, 2018, 128, 4485-4500.	8.2	104
38	Cross Talk from Tubules to Glomeruli. Toxicologic Pathology, 2018, 46, 944-948.	1.8	19
39	Chronic kidney disease alters lipid trafficking and inflammatory responses in macrophages: effects of liver X receptor agonism. BMC Nephrology, 2018, 19, 17.	1.8	16
40	A mechanistic investigation of thrombotic microangiopathy associated with IV abuse of Opana ER. Blood, 2017, 129, 896-905.	1.4	30
41	A perspective on chronic kidney disease progression. American Journal of Physiology - Renal Physiology, 2017, 312, F375-F384.	2.7	98
42	Lysophosphatidic Acid Receptor Antagonism Protects against Diabetic Nephropathy in a Type 2 Diabetic Model. Journal of the American Society of Nephrology: JASN, 2017, 28, 3300-3311.	6.1	47
43	Tubulointerstitial fibrosis can sensitize the kidney to subsequent glomerular injury. Kidney International, 2017, 92, 1395-1403.	5.2	36
44	Blocking TGF-β and β-Catenin Epithelial Crosstalk Exacerbates CKD. Journal of the American Society of Nephrology: JASN, 2017, 28, 3490-3503.	6.1	50
45	Macrophage Cyclooxygenase-2 Protects Against Development of Diabetic Nephropathy. Diabetes, 2017, 66, 494-504.	0.6	66
46	Pyridoxamine reduces postinjury fibrosis and improves functional recovery after acute kidney injury. American Journal of Physiology - Renal Physiology, 2016, 311, F268-F277.	2.7	25
47	Kidneys. Current Opinion in Nephrology and Hypertension, 2016, 25, 174-179.	2.0	35
48	Effects of combination PPARÎ ³ agonist and angiotensin receptor blocker on glomerulosclerosis. Laboratory Investigation, 2016, 96, 602-609.	3.7	10
49	Retinoic Acid Signaling Coordinates Macrophage-Dependent Injury and Repair after AKI. Journal of the American Society of Nephrology: JASN, 2016, 27, 495-508.	6.1	65
50	Quantification and Comparison of Anti-Fibrotic Therapies by Polarized SRM and SHG-Based Morphometry in Rat UUO Model. PLoS ONE, 2016, 11, e0156734.	2.5	14
51	Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein. Archives of Medical Research, 2015, 46, 379-391.	3.3	42
52	Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. Atherosclerosis, 2015, 242, 56-64.	0.8	30
53	Renal fibrosis is not reduced by blocking transforming growth factor-β signaling in matrix-producing interstitial cells. Kidney International, 2015, 88, 503-514.	5.2	61
54	Vitronectin-binding PAI-1 protects against the development of cardiac fibrosis through interaction with fibroblasts. Laboratory Investigation, 2014, 94, 633-644.	3.7	22

#	Article	IF	CITATIONS
55	Kidney Regeneration in Mammals. Nephron Experimental Nephrology, 2014, 126, 50-53.	2.2	13
56	Fibrosis and renal aging. Kidney International Supplements, 2014, 4, 75-78.	14.2	48
57	Animal models of regression/progression of kidney disease. Drug Discovery Today: Disease Models, 2014, 11, 45-51.	1.2	24
58	Mechanisms of Disease Reversal in Focal and Segmental Glomerulosclerosis. Advances in Chronic Kidney Disease, 2014, 21, 442-447.	1.4	20
59	Parietal Epithelial Cell Activation Marker in Early Recurrence of FSGS in the Transplant. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1852-1858.	4.5	99
60	Specific deletion of glycogen synthase kinase-3β in the renal proximal tubule protects against acute nephrotoxic injury in mice. Kidney International, 2012, 82, 1000-1009.	5.2	47
61	Cells Derived from Young Bone Marrow Alleviate Renal Aging. Journal of the American Society of Nephrology: JASN, 2011, 22, 2028-2036.	6.1	43
62	Cell Senescence in the Aging Kidney. Journal of the American Society of Nephrology: JASN, 2010, 21, 1436-1439.	6.1	135
63	Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis. American Journal of Physiology - Renal Physiology, 2010, 298, F683-F691.	2.7	67
64	Models of chronic kidney disease. Drug Discovery Today: Disease Models, 2010, 7, 13-19.	1.2	232
65	The PPARÎ ³ Agonist Pioglitazone Ameliorates Aging-Related Progressive Renal Injury. Journal of the American Society of Nephrology: JASN, 2009, 20, 2380-2388.	6.1	159
66	Regression of Glomerulosclerosis with High-Dose Angiotensin Inhibition Is Linked to Decreased Plasminogen Activator Inhibitor-1. Journal of the American Society of Nephrology: JASN, 2005, 16, 966-976.	6.1	137
67	Selonsertib Enhances Kidney Protection Beyond Standard of Care in a Hypertensive, Secondary Glomerulosclerosis CKD Model. Kidney360, 0, , 10.34067/KID.0001032022.	2.1	2